Use of the Oral Sialogogue “Oriza Tablet” in Reducing Drug-Induced Xerostomia in Patients with Overactive Bladder or Neurogenic Bladder: Randomized Clinical Study
Issued Date
2024-10-01
Resource Type
ISSN
1934578X
eISSN
15559475
Scopus ID
2-s2.0-85208813694
Journal Title
Natural Product Communications
Volume
19
Issue
10
Rights Holder(s)
SCOPUS
Bibliographic Citation
Natural Product Communications Vol.19 No.10 (2024)
Suggested Citation
Piyawannarat S., Sirisreetreelux P., Rattapornsompong W., Tancharoen S., Viseshsindh W. Use of the Oral Sialogogue “Oriza Tablet” in Reducing Drug-Induced Xerostomia in Patients with Overactive Bladder or Neurogenic Bladder: Randomized Clinical Study. Natural Product Communications Vol.19 No.10 (2024). doi:10.1177/1934578X241287065 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102082
Title
Use of the Oral Sialogogue “Oriza Tablet” in Reducing Drug-Induced Xerostomia in Patients with Overactive Bladder or Neurogenic Bladder: Randomized Clinical Study
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Purpose: Evaluate the clinical efficacy of “Oriza tablet” (OT) for patients with neurologic bladder or overactive bladder affected by xerostomia due to receiving antimuscarinic drugs. Material and methods: This was a randomized clinical trial. Twenty-eight patients (median age = 64 years) with xerostomia were divided into two groups: OT (intervention group) and placebo (control) group. Both groups comprised 14 patients each. Objective: We assessed severity using a questionnaire for the subjective evaluation of xerostomia. Objective evaluation was undertaken for the stimulated salivary flow rate (SSFR). Xerostomia evaluation took place before treatment (baseline) as well as 2 weeks and 4 weeks after treatment. Results: The xerostomia score decreased significantly (p < 0.05) in the OT group compared to the placebo group, with scores of 2.75 versus 4.4 at 2 weeks and 2.19 versus 4.13 at 4 weeks, respectively. The SSFR increased significantly (p < 0.05) in the OT group compared to the placebo group, with SSFR of 2 versus 1.2 at 2 weeks and 1.85 versus 1.1 at 4 weeks, respectively. Throughout the trial, no patient discontinued taking antimuscarinic medications. There were no adverse effects noted. Conclusion: Continuous daily use of OT for 4 weeks reduced xerostomia symptoms and increased saliva production in patients suffering from neurologic bladder or overactive bladder who received antimuscarinic medications. Clinical trial registration: The study was registered with The Thai Clinical Trials Registry (TCTR). ID: TCTR20240715015.